How Lucis AI-Driven Preventive Health Platform Achieved Measurable Outcomes for 10,000+ European Users

At the heart of Lucis’s pitch to investors is early evidence that its data-driven, physician-supervised approach to prevention measurably improves health. Among its first 10,000 users across France, the UK, Ireland, and Portugal, 75% of those who completed a six-month follow-up improved at least three biomarkers without medication, and more than 80% opted to retest — both signals that the platform drives sustained behavioral change .

How the Lucis platform detects hidden health risks

The platform relies on venous blood draws processed through more than 400 accredited partner laboratories, including Eurofins and Randox . Each comprehensive baseline check-up analyzes over 110 blood biomarkers spanning metabolic health, cardiovascular risk, hormones (including sexual hormones), inflammation, stress and recovery markers, nutrient levels (vitamins and minerals), liver and kidney function, and thyroid markers . A follow-up test at six months examines 60+ biomarkers to track progress .

Rather than handing users a raw lab report, Lucis feeds the results into an AI companion app that combines biomarker data, longitudinal trends, and medical context to generate personalized guidance across nutrition, supplementation, sleep, physical activity, environment, and mental health . All recommendations are reviewed by a clinical team of more than 10 physicians and a medical board led by an MD/PhD before reaching the user . Optional add-on panels include a gut microbiome analysis (€150) and a food intolerance assessment covering 50 to 100 foods (€300) .

The platform is GDPR compliant, ISO 27001 certified, and HDS-certified for health data hosting, reflecting the sensitive nature of the data it handles .

What the biomarker panel covers

Lucis groups its biomarker results into simplified wellness indices to help users understand key health pillars. Biomarkers tracked include TSH and fT4 for thyroid function, vitamin B12, magnesium, folate, and transferrin saturation for nutritional status, plus hemoglobin and standard metabolic and cardiovascular risk markers . The platform also calculates a biological age estimate that users can track over time .

A hidden epidemic: what the first 10,000 screenings revealed

The company’s early outcomes paint a stark picture of how easily health risks go unnoticed without regular monitoring. At their first comprehensive screening, 99.9% of Lucis users had at least one biomarker outside optimal ranges — often without any prior awareness of the imbalance . This finding underscores the core thesis behind the company: that modern healthcare is overwhelmingly reactive, and that making regular, interpretable biomarker testing accessible can surface early signals of chronic disease years before symptoms emerge.

The platform delivered more than one million individual biomarker tests to its initial user base. Growth velocity has been striking: Lucis went from 500 users in its first four months in Paris to over 10,000 across four countries in under a year, all with a team of approximately 20 people .

The road ahead: Spain, Germany, and Italy

With the new capital, Lucis plans to launch in Spain, Germany, and Italy by the end of 2026, while continuing to develop the AI-driven health companion app that forms the core of its product experience . The company positions itself as what observers have called “the Function Health of Europe” — a reference to the U.S. preventive testing platform that has drawn significant consumer demand .

Lucis explicitly states it does not provide medical diagnoses or replace physicians. Its platform is designed to make regular blood testing as routine a health habit as brushing your teeth, turning cryptic lab numbers into a structured, preventive view of personal health that people can track and improve over time .